How to achieve label-free images without compromising on resolution?

Online Event – Aired on March 7!

Presentation

What’s the difference between holotomography, phase contrast, and quantitative phase imaging? These three imaging techniques are all based on the same label-free principle but can provide differing levels of resolution. This video compares these technologies and their uses in live-cell imaging, from cell counting, to high-content phenotypic analysis.

This video is part of the miniseries Discover label-free imaging technology with Nanolive.
What is holotomography, how does it work and what benefits does this live-cell imaging approach bring to fundamental research and drug development? This miniseries dives into the technology behind Nanolive’s high-content live cell images and explains how holotomography is essential for providing deep phenotypic insights into cellular responses.

You may be interested in this series if you:

  • Are working on preclinical drug development in the biopharmaceutical industry
  • Are an academic research scientist
  • Want to understand drug toxicity and safety without the bias of labels
  • Have a curious mindset and want to learn more about imaging technologies

Read our latest news

Label-free assessment of immunotherapies for liquid tumors

Label-free assessment of immunotherapies for liquid tumors

From activation to target engagement and killing, Nanolive’s revolutionary technology enables the identification of the most effective therapeutic candidates for liquid tumors using live, label-free and advanced automated analysis of effector cell activity and function. Discover the case study data.
Simplifying drug delivery assessment: Industry perspectives

Simplifying drug delivery assessment: Industry perspectives

Optimization of drug delivery systems can become slow, resource intensive, and reliant on incomplete information. With one assay, Nanolive monitors the complete dynamics of drug delivery, reducing phototoxicity from labels and helping teams identify where delivery succeeds or fails.

Subscribe to our newsletter